Advertisement Global Private-Public Partnerships Support Meningococcal Vaccination Programmes - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Future Market Insights

Global Industry Outlook & Business Review

More info about Future Market Insights

Global Private-Public Partnerships Support Meningococcal Vaccination Programmes

Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives.

The last few years have witnessed an increase in several private-public partnerships specifically focusing on vaccine provision in developing countries. Partnerships such as the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need.

The governments of several countries worldwide initiate immunisation programmes periodically and these they are backed by global organisations such as the United Nations Children’s Fund (UNICEF) and the World Health Organisation (WHO), as well as private not-for-profits such as the Global Alliance for Vaccines and Immunization (GAVI).

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is in Brazil. In 2010, the Ezequiel Dias Foundation of Brazil formed a strategic alliance with Novartis Vaccines and Diagnostics for a sustainable supply of Menjugate MenC vaccines for Brazil’s national immunisation programme. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time increase growth in the meningococcal vaccines market.

Factors leading to worldwide adoption of meningococcal vaccination programmes
The global meningococcal vaccines market is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines supported by immunisation alliances and mass vaccination campaigns.

Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating speedy introduction of vaccines in some of the more economically challenged countries of the Middle East and Africa (MENA) region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the US and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further increasing the growth trajectory of the global market for meningococcal vaccines.

According to Future Market Insights’ (FMI) projections, the global market for meningococcal vaccines is expected to reach $6bn by the end of 2028 from a valuation of $2.3m in 2017, reflecting a compound annual growth rate (CAGR) of 9.2% during the 10-year period from 2018 to 2028.

GlaxoSmithKline to lead the global meningococcal vaccines market with around 50% market share recorded in 2017.

The global meningococcal vaccines market is highly consolidated, with GlaxoSmithKline and Sanofi together holding around 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017.

Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies. Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets, while GlaxoSmithKline has five active pipeline programmes for meningococcal vaccines, which are all in Phase II clinical stage. The addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.

To request a sample report, click here.

To find out more information about report methodology, click here.